Biggest News Aggregation in the World

Page 6 - Temre Johnson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Temre Johnson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Temre Johnson Today - Breaking & Trending Today

Mirati Therapeutics to Present Late-Breaking Data That Advance the Understanding of Synthetic Lethal PRMT5 Inhibitors in MTAP-Deleted Cancers at AACR 2021 - Vimarsana News

Mirati Therapeutics to Present Late-Breaking Data That Advance the Understanding of Synthetic Lethal PRMT5 Inhibitors in MTAP-Deleted Cancers at AACR 2021

Published: March 10, 2021

Share this article Share this article SAN DIEGO, March 10, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced it will present initial preclinical data on the Company's synthetic lethal PRMT5 inhibitor during a late-breaking minisymposium at the American Association for Cancer Research (AACR) Virtual Annual Meeting taking place April 10-15, 2021. "At Mirati, we are applying leading-edge drug discovery strategies, such as synthetic lethality, to translate this exciting research approach into meaningful, targeted therapeutic ...

Source: prnewswire.com

Related Topics:

United States Matthew Marx Priyanka Shah James Christensen Temre Johnson Exchange Commission American Association For Cancer Research Mirati Therapeutics Inc Mirati Therapeutics American Association Cancer Research Virtual Annual Meeting Breaking Minisymposium ஒன்றுபட்டது மாநிலங்களில்மேத்யூ மார்க்ஸ்பிரியாங்க ஷா ஜேம்ஸ் கிறிஸ்டென்சன்பரிமாற்றம் தரகு அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சி மிரட்டி சிகிச்சை இன்க்மிரட்டி சிகிச்சை அமெரிக்கன் சங்கம்புற்றுநோய் ஆராய்ச்சி மெய்நிகர் ஆண்டு சந்தித்தல்

Mirati Therapeutics Reports Fourth Quarter And Full-Year 2020 Financial Results And Recent Corporate Updates - Vimarsana News

Mirati Therapeutics Reports Fourth Quarter And Full-Year 2020 Financial Results And Recent Corporate Updates

Published: February 25, 2021

Share this article Share this article SAN DIEGO, Feb. 25, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today reported financial results for the fourth quarter and full year of 2020, which reflect the company's progress across its clinical and discovery pipeline and strength as it expands its operational structure and capabilities in preparation for potential commercialization in the United States. "Our commitment to patients with cancer has enabled us to advance our two clinical programs, adagrasib and sitravatinib, as well as our pr...

Source: prnewswire.com